Literature DB >> 34019104

Manipulating oligodendrocyte intrinsic regeneration mechanism to promote remyelination.

Fabien Binamé1, Lucas D Pham-Van1, Dominique Bagnard2.   

Abstract

In demyelinated lesions, astrocytes, activated microglia and infiltrating macrophages secrete several factors regulating oligodendrocyte precursor cells' behaviour. What appears to be the initiation of an intrinsic mechanism of myelin repair is only leading to partial recovery and inefficient remyelination, a process worsening over the course of the disease. This failure is largely due to the concomitant accumulation of inhibitory cues in and around the lesion sites opposing to growth promoting factors. Here starts a complex game of interactions between the signalling pathways controlling oligodendrocytes migration or differentiation. Receptors of positive or negative cues are modulating Ras, PI3K or RhoGTPases pathways acting on oligodendrocyte cytoskeleton remodelling. From the description of this intricate signalling network, this review addresses the extent to which the modulation of the global response to inhibitory cues may pave the route towards novel therapeutic approaches for myelin repair.

Entities:  

Keywords:  Migration; Multiple sclerosis; Myelin repair; Oligodendrocytes; Signalling pathways; Therapy

Year:  2021        PMID: 34019104     DOI: 10.1007/s00018-021-03852-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  192 in total

1.  Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?

Authors:  Christina Marik; Paul A Felts; Jan Bauer; Hans Lassmann; Kenneth J Smith
Journal:  Brain       Date:  2007-11       Impact factor: 13.501

2.  Pattern of remyelination in the CNS.

Authors:  W F Blakemore
Journal:  Nature       Date:  1974-06-07       Impact factor: 49.962

Review 3.  The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases.

Authors:  Grégory Conductier; Nicolas Blondeau; Alice Guyon; Jean-Louis Nahon; Carole Rovère
Journal:  J Neuroimmunol       Date:  2010-07-27       Impact factor: 3.478

4.  Long-term remyelination fails to reconstitute normal thickness of central myelin sheaths.

Authors:  S K Ludwin; M Maitland
Journal:  J Neurol Sci       Date:  1984-05       Impact factor: 3.181

Review 5.  Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis.

Authors:  H Lassmann
Journal:  Neuropathol Appl Neurobiol       Date:  2011-12       Impact factor: 8.090

6.  A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination.

Authors:  Doron Merkler; Tristan Ernsting; Martin Kerschensteiner; Wolfgang Brück; Christine Stadelmann
Journal:  Brain       Date:  2006-05-19       Impact factor: 13.501

Review 7.  Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.

Authors:  Bridgette D Semple; Thomas Kossmann; Maria Cristina Morganti-Kossmann
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

Review 8.  Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases.

Authors:  Harald Neumann; Isabelle M Medana; Jan Bauer; Hans Lassmann
Journal:  Trends Neurosci       Date:  2002-06       Impact factor: 13.837

9.  Multiple sclerosis: distribution of inflammatory cells in newly forming lesions.

Authors:  Andrew P D Henderson; Michael H Barnett; John D E Parratt; John W Prineas
Journal:  Ann Neurol       Date:  2009-12       Impact factor: 10.422

10.  The role of angiogenesis in the pathology of multiple sclerosis.

Authors:  Justin Lengfeld; Tyler Cutforth; Dritan Agalliu
Journal:  Vasc Cell       Date:  2014-11-28
View more
  1 in total

Review 1.  The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use.

Authors:  Dafni Birmpili; Imane Charmarke Askar; Kévin Bigaut; Dominique Bagnard
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.